Cenicriviroc (CVC)

DRUG2 trials

Sponsors

Novartis Pharmaceuticals, Charite University, Berlin, Germany

Conditions

Covid19Non-alcoholic Steatohepatitis (NASH)

Phase 2

Study of Safety, Tolerability, and Efficacy of a Combination Treatment of LJN452 and CVC in Adult Patients With NASH and Liver Fibrosis

CompletedNCT03517540

Novartis PharmaceuticalsNon-alcoholic Steatohepatitis (NASH)

Start: 2018-09-11End: 2020-10-15Updated: 2022-04-29

Charité Trial of Cenicriviroc (CVC) Treatment for COVID-19 Patients

TerminatedNCT04500418

Charite University, Berlin, GermanyCovid19

Start: 2020-08-25End: 2021-07-27Updated: 2022-03-29

Related Papers

NAFLD and NAFLD Related HCC: Emerging Treatments and Clinical Trials.

2025-01-019 citations

Utility of AI digital pathology as an aid for pathologists scoring fibrosis in MASH.

2024-11-289 citations

A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial.

2019-11-1389 citations